Latest news with #ThomasJ
Associated Press
5 days ago
- Business
- Associated Press
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. (URGN)
By Gainey McKenna & Egleston Published [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired UroGen Pharma Ltd. ('EuroGen' or the 'Company') (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, both dates inclusive (the 'Class Period'). The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) UroGen's ENVISION clinical study for UGN-102 was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (ii) as a result, UroGen would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (iii) UroGen failed to heed the U.S. Food and Drug Administration's ('FDA') warnings about the study design used to support a new drug application ('NDA') for UGN-102; and (iv) as a result, there was a substantial risk that the NDA for UGN-102 would not be approved. Investors who purchased or otherwise acquired shares of EuroGen should contact the Firm prior to the July 28, 2025 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] . Please visit our website at for more information about the firm. The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world's population sees AP journalism every day.
Yahoo
24-04-2025
- General
- Yahoo
Thomas J. O'Connor Adoption Center celebrates devoted volunteers
SPRINGFIELD, Mass. (WWLP) – The Thomas J. O'Connor animal control and adoption center in Springfield put a spotlight on the volunteers who have dedicated themselves to helping animals in need. The TJO staff was joined by Mayor Domenic Sarno to put on the appreciation party to celebrate their volunteers, and say 'thank you' for their efforts. TJO says thousands of animals go through their doors every year, and the volunteers go above and beyond to make sure they are loved and cared for. Interim Exec. Director Heather Cahillane told 22News, 'It's one of the most rewarding things that you can imagine. You see animals come in, sometimes at the worst part of their life—and you get to see them heal, bloom, and blossom—go to a new adoptive home— it's a pretty amazing feeling.' TJO is also in need of people to foster animals. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Associated Press
28-03-2025
- Business
- Associated Press
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Actinium Pharmaceuticals, Inc. (ATNM)
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Actinium Pharmaceuticals, Inc. ('Actinium' or the 'Company') (NYSE: ATNM) securities between October 31, 2022 and August 2, 2024, inclusive (the 'Class Period'). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws. The Complaint alleges that Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that the Defendants failed to disclose to investors that: (1) the Company's data from Sierra Trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of the Company's Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate the Sierra Trial's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of the Company's Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4), as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. According to the Complaint, the truth began to reach the market on August 5, 2024, when the Company announced that 'the analyses from the Sierra Trial do not adequately support a BLA filing for Iomab-B and requires an additional clinical study,' and Actinium's stock price suffered significant declines, harming investors. Investors who purchased or otherwise acquired shares of Actinium should contact the Firm prior to the May 26, 2025 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Associated Press
14-03-2025
- Business
- Associated Press
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN)
NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Geron Corporation ('Geron' or the 'Company') (NASDAQ: GERN) securities between June 7, 2024 and February 25, 2025, inclusive (the 'Class Period'). The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company created the false impression that they possessed reliable information pertaining to its projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations; (ii) in truth, the Company's optimistic reports of Rytelo's launch success and potential growth fell short of reality as the impacts of seasonality, existing competition, and the burden of continued monitoring played a much more significant role in patient starts than defendants had implied; and (iii) Rytelo lacked the necessary awareness to penetrate the market, resulting in an inability for Geron to capitalize on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside the academic setting. The Complaint further alleges that on February 26, 2025, the Company announced its financial results for the fourth quarter of fiscal year 2024, disclosing that Rytelo's growth had flattened over the preceding months, attributing the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. On this news, the Company's stock price declined more than 32%. Investors who purchased or otherwise acquired shares of Geron should contact the Firm prior to the May 12, 2025 lead plaintiff motion deadline. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
